Global Gene Therapy Market 2018-2022

遺伝子治療の世界市場2018-2022

◆タイトル:Global Gene Therapy Market 2018-2022
◆商品コード:IRTNTR23832
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年9月18日
◆ページ数:112
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、遺伝子治療の世界市場について調査・分析し、市場概要、市場環境、遺伝子治療市場規模、治療領域別(腫瘍科、CNS、眼科学、希少疾患、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。主な分析対象企業は、Biogen, Gilead, Novartis, Orchard Therapeutics, Spark Therapeuticsなどです。
・エグゼクティブサマリー
・調査範囲・調査手法
・遺伝子治療の世界市場概要
・遺伝子治療の世界市場環境
・遺伝子治療の世界市場動向
・遺伝子治療の世界市場規模
・遺伝子治療の世界市場:業界構造分析
・遺伝子治療の世界市場:治療領域別(腫瘍科、CNS、眼科学、希少疾患、その他)
・遺伝子治療の世界市場:地域別市場規模・分析
・遺伝子治療の北米市場規模・予測
・遺伝子治療のヨーロッパ・中東・アフリカ市場規模・予測
・遺伝子治療のアジア太平洋市場規模・予測
・遺伝子治療の主要国分析
・遺伝子治療の世界市場:意思決定フレームワーク
・遺伝子治療の世界市場:成長要因、課題
・遺伝子治療の世界市場:競争環境
・遺伝子治療の世界市場:関連企業情報(ベンダー分析)

About Gene Therapy
Gene therapy is one of the most recent innovations in the pharmaceutical industry for the treatment of serious, life-threatening diseases, typically in the areas of oncology and cardiovascular. It is the usage of modified gene injected into the patient’s body primarily through virus as a vector. This transmitted gene reaches the intended site to kill or treat the infected cell, thus curing the disease.
Technavio’s analysts forecast the Global Gene Therapy Market to grow at a CAGR of 22.42% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the gene therapy market. To calculate the market size, the report considers the revenue generated by the use of gene therapy across the globe.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, gene therapy market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Biogen
• Gilead
• Novartis
• Orchard Therapeutics
• Spark Therapeutics
Market driver
• Market entry of novel molecules during the forecast period
• For a full, detailed list, view our report

Market challenge
• High treatment costs
• For a full, detailed list, view our report

Market trend
• Growing research in gene therapy for CVDs and orphan diseases
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY THERAPY AREA
• Segmentation by therapy area
• Comparison by therapy area
• Oncology – Market size and forecast 2017-2022
• CNS – Market size and forecast 2017-2022
• Ophthalmology – Market size and forecast 2017-2022
• Rare diseases – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Market opportunity by therapy area
PART 08: PIPELINE
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Key leading countries
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Growing research in gene therapy for CVDs and orphan diseases
• Growing strategic alliances
• Increasing government initiatives
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Biogen
• Gilead
• Novartis
• Orchard Therapeutics
• Spark Therapeutics
PART 16: APPENDIX
• List of abbreviations



Exhibit 01: Parent market: Global regenerative medicines market
Exhibit 02: Global regenerative medicines market segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global gene therapy market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global gene therapy market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2017
Exhibit 18: Global gene therapy market – Market share by therapy area 2017-2022 (%)
Exhibit 19: Comparison by therapy area
Exhibit 20: Global gene therapy market by oncology – Market size and forecast 2017-2022 ($ mn)
Exhibit 21: Global gene therapy oncology market – Year-over-year growth 2018-2022 (%)
Exhibit 22: Global gene therapy market by CNS – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global gene therapy market by CNS – Year-over-year growth 2018-2022 (%)
Exhibit 24: Global gene therapy market by ophthalmology – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Global gene therapy market by ophthalmology – Year-over-year growth 2018-2022 (%)
Exhibit 26: Global gene therapy market by rare diseases – Market size and forecast 2017-2022 ($ mn)
Exhibit 27: Global gene therapy market by rare diseases – Year-over-year growth 2018-2022 (%)
Exhibit 28: Global gene therapy market by others – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Global gene therapy market by others – Year-over-year growth 2018-2022 (%)
Exhibit 30: Market opportunity by therapy area
Exhibit 31: Global gene therapy market pipeline: Overview
Exhibit 32: Gene therapy in pipeline: Overview
Exhibit 33: Customer landscape
Exhibit 34: Global gene therapy market – Market share by geography 2017-2022 (%)
Exhibit 35: Regional comparison
Exhibit 36: Gene therapy market in Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: Gene therapy market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 38: Gene therapy market in EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 39: Gene therapy market in EMEA – Year-over year-growth 2018-2022 (%)
Exhibit 40: Gene therapy market in APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 41: Gene therapy market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: Biogen – Overview
Exhibit 50: Biogen – Business segments
Exhibit 51: Biogen – Organizational developments
Exhibit 52: Biogen – Geographic focus
Exhibit 53: Biogen – Key offerings
Exhibit 54: Biogen – Key customers
Exhibit 55: Gilead – Overview
Exhibit 56: Gilead – Business segments
Exhibit 57: Gilead – Organizational developments
Exhibit 58: Gilead – Geographic focus
Exhibit 59: Gilead – Key offerings
Exhibit 60: Gilead – Key customers
Exhibit 61: Novartis: Overview
Exhibit 62: Novartis – Business segments
Exhibit 63: Novartis – Organizational developments
Exhibit 64: Novartis – Geographic focus
Exhibit 65: Novartis – Segment focus
Exhibit 66: Novartis – Key offerings
Exhibit 67: Novartis – Key customers
Exhibit 68: Orchard Therapeutics – Overview
Exhibit 69: Orchard Therapeutics – Business segments
Exhibit 70: Orchard Therapeutics – Organizational developments
Exhibit 71: Orchard Therapeutics – Key offerings
Exhibit 72: Orchard Therapeutics – Key customers
Exhibit 73: Spark Therapeutics – Overview
Exhibit 74: Spark Therapeutics – Business segments
Exhibit 75: Spark Therapeutics – Organizational developments
Exhibit 76: Spark Therapeutics – Key offerings
Exhibit 77: Spark Therapeutics – Key customers



【掲載企業】

Biogen, Gilead, Novartis, Orchard Therapeutics, Spark Therapeutics

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[遺伝子治療の世界市場2018-2022]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆